🚨 An experimental, personalized vaccine using #mRNA to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group. New results from a phase 1 clinical trial, being presented at #AACR26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later. “These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines. Learn more about these findings: bit.ly/3QuIiaL @AACR